口服有效的CVS-1123可以预防有意识的狗的冠状动脉血栓形成
G R Cousins1, G S Friedrichs, Y Sudo
1Department of Pharmacology, University of Michigan Medical School, Ann Arbor 48109-0632, USA.
Circulation
|October 1, 1996
概括
口服直接血素抑制剂CVS-1123在动脉损伤后有效地预防了狗的冠状动脉血栓形成. 这项研究强调了CVS-1123作为临床使用的潜在抗血栓剂.
科学领域:
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
- 血栓形成研究研究
背景情况:
- 研究了CVS-1123的口服疗效,CVS-1123是一种直接的血栓激素抑制剂.
- 评估了血栓抑制的潜力,以减少在动脉损伤后的封闭性冠状动脉血栓形成.
研究的目的:
- 为了确定CVS-1123的口服是否可以预防动脉血栓形成.
- 在动脉壁损伤的狗模型中评估CVS-1123的疗效.
主要方法:
- 在引起动脉壁损伤之前,有意识的狗接受了口服CVS-1123 (20 mg/kg) 或安慰剂.
- 在受伤后24小时内监测冠状动脉通透度.
- 测量了血药物度和ex vivo血小板聚合.
主要成果:
- 在接受CVS-1123治疗的11只狗中,有8只保持了冠状动脉通透.
- 所有接受安慰剂治疗的10只狗都发生了封闭性动脉血栓.
- CVS-1123抑制了血小板聚合和延长了激活的部分血栓形成时间.
结论:
- 在实验性动脉损伤模型中,口服CVS-1123有效降低了血栓形成.
- 像CVS-1123这样的血特异性抑制剂可能为肝素提供替代品.
- CVS-1123显示出长期抗凝治疗的前景.
相关概念视频
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...


